Scarica l'app Stockscreener
3.81
4.27%
-0.17
Dopo l'orario di chiusura:
3.85
0.04
+1.05%
Precedente Chiudi:
$3.98
Aprire:
$3.95
Volume 24 ore:
1.81M
Relative Volume:
1.58
Capitalizzazione di mercato:
$282.81M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-22.20
EPS:
-0.1716
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
-0.26%
1M Prestazione:
-4.27%
6M Prestazione:
+22.51%
1 anno Prestazione:
-70.19%
Intervallo 1D:
$3.6601
$4.0755
Intervallo di 1 settimana:
$3.47
$4.0755
Portata 52W:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Confronta CATX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.81 | 276.13M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
129.40 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Oppenheimer lowers Perspective Therapeutics stock price target to $14 - Investing.com
Perspective Therapeutics: Navigating the Theranostics Frontier with Precision and Purpose - AInvest
Perspective Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Perspective Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Perspective Therapeutics Reports Promising Study Results at ASCO - TipRanks
Perspective Therapeutics Inc (CATX) Q2 2025 Earnings: EPS Loss o - GuruFocus
Perspective Therapeutics Reports Q2 Loss - Nasdaq
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - The Globe and Mail
Perspective Therapeutics (CATX) posts Q2 2025 results and updated presentation | CATX SEC FilingForm 8-K - Stock Titan
Cancer Drug Developer Perspective Sees Treatment Success: 4 of 7 Patients Respond in Phase 1/2a Trial - Stock Titan
Perspective Therapeutics Q2 Earnings Preview: Analysts Expect Losses and Revenue Decline - AInvest
Can Perspective Therapeutics Inc. hit a new high this monthFree News Based Entry Opportunity Alerts - Newser
Multi factor analysis applied to Perspective Therapeutics Inc.Free Value Investing Picks With Stability - Newser
Perspective Therapeutics, Inc. shares rise 3.09% after-hours following a corporate update on clinical progress and strategic positioning. - AInvest
Published on: 2025-08-04 12:18:12 - Jammu Links News
When is Perspective Therapeutics Inc. stock expected to show significant growthInvest smarter with expert stock recommendations - Jammu Links News
Why is Perspective Therapeutics Inc. stock attracting strong analyst attentionConsistent triple returns - Jammu Links News
What are the technical indicators suggesting about Perspective Therapeutics Inc.Unlock your portfolio’s hidden potential - Jammu Links News
How does Perspective Therapeutics Inc. generate profit in a changing economyBuild wealth steadily with proven methods - Jammu Links News
What are the latest earnings results for Perspective Therapeutics Inc.Unlock rapid growth potential in your portfolio - Jammu Links News
How many analysts rate Perspective Therapeutics Inc. as a “Buy”Build a strong portfolio for long-term success - Jammu Links News
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) vs. Motus GI (NASDAQ:MOTS) Critical Contrast - Defense World
How to read the order book for Perspective Therapeutics Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation - TipRanks
Live market analysis of Perspective Therapeutics Inc.Predictive AI Engine for Smart Investing - Newser
Applying chart zones and confluence areas to Perspective Therapeutics Inc.Short-Term AI-Based Stock Price Forecast - Newser
What makes Perspective Therapeutics Inc. stock price move sharplySwing Candidate List with Trade Cues - Newser
When is the best time to exit Perspective Therapeutics Inc.Smart Trade Mapping with Entry Details - Newser
How strong is Perspective Therapeutics Inc. company’s balance sheetTop Growth Tips For Consistent Profits - jammulinksnews.com
Perspective Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowAI Driven Buy Alert Trade Blueprint Released - metal.it
Volume spikes in Perspective Therapeutics Inc. stock – what they meanSector Rotation Outlook With Historical Summary - Newser
Is It Too Late to Sell Perspective Therapeutics Inc.Watchlist for Smart Swing Trading Updated - metal.it
Perspective Therapeutics shares fall 3.16% intraday after FDA approval conference call for Sephience. - AInvest
Is Perspective Therapeutics Inc. the Top Chart Pick This WeekCommunity Strategy With High Win Rate Backtested - metal.it
How volatile is Perspective Therapeutics Inc. stock compared to the marketFinancial News Outlook For 2025 - jammulinksnews.com
Is it the right time to buy Perspective Therapeutics Inc. stockAI Powered Target Finder For Consistent Profits - Jammu Links News
What is the dividend policy of Perspective Therapeutics Inc. stockStock Market Review That Work - Jammu Links News
Perspective Therapeutics shares fall 1.48% premarket after Unicycive Therapeutics receives FDA CRL. - AInvest
Volume spikes in Perspective Therapeutics Inc. stock – what they mean Asset Growth Pattern and Return Summary - Newser
What is the risk reward ratio of investing in Perspective Therapeutics Inc. stockInvest with confidence backed by data - Jammu Links News
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Perspective Therapeutics Inc Azioni (CATX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Spoor Johan M. | Chief Executive Officer |
Mar 28 '25 |
Buy |
2.21 |
4,650 |
10,288 |
4,650 |
| Williamson Robert F III | Director |
Mar 31 '25 |
Buy |
2.14 |
38,145 |
81,775 |
108,982 |
| Williamson Robert F III | Director |
Mar 28 '25 |
Buy |
2.27 |
22,192 |
50,376 |
70,837 |
| Graham Juan | Chief Financial Officer |
Mar 28 '25 |
Buy |
2.25 |
33,333 |
74,946 |
35,354 |
| Woods Lori A | Director |
Mar 31 '25 |
Buy |
2.13 |
23,475 |
49,999 |
183,460 |
| HENSON HEIDI | Director |
Dec 04 '24 |
Buy |
3.85 |
25,975 |
100,004 |
25,975 |
| Spoor Johan M. | CEO |
Dec 04 '24 |
Buy |
3.77 |
8,000 |
30,132 |
36,257 |
| Williamson Robert F III | Director |
Nov 25 '24 |
Buy |
3.64 |
6,266 |
22,814 |
430,058 |
| Hunt Jonathan Robert | Chief Financial Officer |
Nov 25 '24 |
Buy |
3.82 |
12,829 |
48,974 |
48,800 |
| Spoor Johan M. | CEO |
Nov 25 '24 |
Buy |
3.78 |
14,500 |
54,868 |
152,072 |
0.31%
1.36%
Capitalizzazione:
|
Volume (24 ore):